Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMVP Health Care Perjeta Prior Auth Coverage | Open…
    Ask Trek AI about this page
    CurrentMVP Health CarePolicy N/A

    Perjeta (pertuzumab) medical benefit coverage

    Customize your policy alerts

    Sign up for all MVP Health Care policy alerts

    Know when MVP Health Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines MVP Health Care Medicaid medical benefit coverage and prior authorization requirements for Perjeta (pertuzumab) for cancer diagnoses, including on-label and off-label use, and applicable administration and billing codes.

    Policy Summary
    PayerMVP Health Care
    PolicyPerjeta (pertuzumab) medical benefit coverage
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateApr 1, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization through the MVP Cancer Guidance Program before using Perjeta for a cancer diagnosis.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    J9306HCPCS
    96413CPT
    Prior authorization

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Auth
    Retro-reviewReview

    Coverage Criteria for Perjeta (pertuzumab)

    On-label cancer use

    Covered when ALL of the following are met

    On-label first-line metastatic breast cancer: Perjeta is indicated for first-line treatment of HER2-positive metastatic breast cancer in combination with trastuzumab and docetaxel and on-label use is covered under the member's medical benefit

    On-label use is subject to retro-review and prior authorization per MVP Cancer Guidance Program

    Authorization for cancer diagnoses: Use of Perjeta for a cancer diagnosis requires prior authorization through the MVP Cancer Guidance Program

    Failure to obtain authorization may result in denial

    Off-label use

    Covered when ALL of the following are met

    Off-label prior authorization: Off-label use of Perjeta requires prior authorization and must meet MVP's clinical coverage criteria for Experimental or Investigational Procedures and Off-Label use of FDA Approved Drugs

    Also subject to related MVP policies (e.g., Behavioral Health Services, Drugs and Treatments; Clinical Trials Policy)

    Perjeta used for indications outside the FDA‑approved labeling is considered off‑label. Off‑label use is eligible for coverage only when it meets MVP’s requirements for prior authorization and also satisfies MVP’s clinical coverage criteria for Experimental or Investigational Procedures and the policy on Off‑Label use of FDA Approved Drugs. Off‑label requests that do not meet those related clinical coverage policies are not authorized.

    Billing and Coding

    Covered HCPCS CodesHCPCSCovered
    J9306Injection; pertuzumab, 1 mg
    Administration CPT CodesCPT
    96413Chemotherapy administration, intravenous infusion technique; up to 1 hour; single or initial substance/drug

    Provider Actions and Authorization Requirements

    Prior Authorization

    Perjeta prior authorization required

    Perjeta (pertuzumab) used for a cancer diagnosis requires prior authorization through the MVP Cancer Guidance Program. For off‑label indications, prior authorization is also required and those uses must meet MVP's clinical coverage criteria for Experimental or Investigational Procedures and related MVP policies.

    • Covered HCPCS code: J9306 must be included on authorization requests when applicable.
    • Off-label uses must meet MVP policies for Experimental or Investigational Procedures and Off-Label use of FDA Approved Drugs.
    Step Therapy

    Obtain MVP Cancer Guidance Program authorization

    Obtain authorization through the MVP Cancer Guidance Program before initiating Perjeta for any cancer diagnosis; there are no specific step agents or failure requirements listed in this policy, but authorization is required as a condition of coverage.

    • Authorization expectation applies both to on‑label and off‑label cancer uses per the MVP Cancer Guidance Program.

    Background

    Perjeta (pertuzumab) is a HER2‑targeted monoclonal antibody included in this policy as an agent requiring authorization when used for cancer diagnoses. Per MVP, use of Perjeta for a cancer diagnosis is subject to the MVP Cancer Guidance Program prior authorization process; off‑label cancer indications additionally must meet MVP’s experimental/investigational and off‑label drug coverage criteria.

    Definitions

    Perjeta (pertuzumab) definition — drug description
    Generic namepertuzumab
    Brand namePerjeta
    Drug classHumanized recombinant monoclonal antibody (HER2-targeted)
    Mechanism of actionBlocks ligand-dependent heterodimerization of HER2 and other EGFR family receptors, inhibiting intracellular signaling leading to growth arrest and apoptosis
    Indication (example)Indicated for first-line treatment of HER2-positive metastatic breast cancer in combination with trastuzumab and docetaxel

    Initial Therapy Criteria

    Initial therapy

    On-label initial indication

    First-line HER2+ metastatic breast cancer: Perjeta in combination with trastuzumab and docetaxel for first-line treatment of HER2-positive metastatic breast cancer

    On-label use is covered under the medical benefit and is subject to retro-review and prior authorization per MVP Cancer Guidance Program

    Step Therapy and Prior Requirements

    StepRequirement
    1Authorization per MVP Cancer Guidance Program is required before use for any cancer diagnosis; no specific step agents or prior failures are listed in the policy.

    Site of Care and Administration

    Billing Rule

    Infusion administration billing

    When Perjeta is administered in an infusion setting, bill chemotherapy infusion administration using CPT 96413 (IV infusion, up to 1 hour) for the single or initial substance/drug.

    • Code: 96413 — Chemotherapy administration, intravenous infusion technique; up to 1 hour; single or initial substance/drug.
    Policy Summary
    PayerMVP Health Care
    PolicyPerjeta (pertuzumab) medical benefit coverage
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateApr 1, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization through the MVP Cancer Guidance Program before using Perjeta for a cancer diagnosis.
    SourceLink
    On This Page
    Coverage Criteria for Perjeta (pertuzumab)Billing and CodingProvider Actions and Authorization RequirementsBackgroundDefinitionsInitial Therapy CriteriaStep Therapy and Prior RequirementsSite of Care and Administration
  1. Failure to obtain authorization may lead to claim denial (see denial risk block).
  2. Documentation Required

    Documentation and retro‑review requirements

    On‑label use of Perjeta is covered under the member's medical benefit but is subject to retro‑review; off‑label use requires prior authorization and must meet MVP's clinical coverage criteria and related policies.

    • Document indication (on‑label vs off‑label) and supporting clinical information in the medical record to support retrospective review or prior authorization requests.
    • Off‑label requests must reference applicable MVP policies (Experimental or Investigational Procedures; Off‑Label use of FDA Approved Drugs; Behavioral Health Services, Drugs and Treatments; Clinical Trials Policy).
    Denial Risk

    Denial risk if authorization not obtained

    Failure to obtain the required prior authorization through the MVP Cancer Guidance Program for Perjeta when used for a cancer diagnosis may result in denial of coverage.

    • Prior authorization is a condition of coverage for cancer indications; verify approval before administration.
    • For off‑label uses, ensure authorization and compliance with MVP off‑label/experimental criteria to avoid denial.